{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-005116","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.255202+00:00","generated_at":"2026-06-27T19:33:19.926004+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC Pharma reports $280.8M cash; pipeline milestones extend into 2023","bullets":["Cash, cash equivalents and investments of $280.8M as of Dec 31, 2021; funds operations into first half of 2024.","ORIC-101 Phase 1b updates from two combination trials expected in first half of 2022.","Initial Phase 1b data for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate cancer) expected in first half of 2023.","Two discovery programs advanced into lead optimization; new program/indication to be announced in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-005116","json":"https://secwatch.observer/filing/0001193125-22-005116.json","markdown":"https://secwatch.observer/filing/0001193125-22-005116.md","text":"https://secwatch.observer/filing/0001193125-22-005116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312522005116/0001193125-22-005116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312522005116/d243804d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:33:19.926004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}